Drospirenone and its antialdosterone properties

References

• Muhn P, Fuhrmann U, Fritzemeier K H, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci 1995; 761: 311–335
   PubMed Web of Science ®Google Scholar
• Fuhrmann U, Krattenmacher R, Slater E P, Fritzemeier K H. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996; 54: 243–251
   PubMed Web of Science ®Google Scholar
• Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progesterone. Contraception 2000; 62: 29–38
   PubMed Web of Science ®Google Scholar
• Losert W, Casals-Stenzel J, Buse M. Progestogens with antimineralocorticoid activity. Arzneimittelforschung 1985; 35: 459–471
   PubMed Web of Science ®Google Scholar
• Pollow K, Juchem M, Elger W, Jacobi N, Hoffmann G, Mobus V. Dihydrospirorenone (ZK30595): a novel synthetic progesterone – characterization of binding to different receptor proteins. Contraception 1992; 46: 561–574
   PubMed Web of Science ®Google Scholar
• Rübig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climacteric 2003; 6(Suppl 3)49–55
   PubMedGoogle Scholar
• Schindler A E, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas 2003; 46(Suppl 1)S7–S16
   PubMed Web of Science ®Google Scholar
• Oelkers W, Schöneshöfer M, Schultze G, et al. Prolonged infusions of Ile5-angiotensin-II in sodium replete and deplete man: effects of aldosterone, ACTH, cortisol, blood pressure and electrolyte balance. J Clin Endocrinol Metab 1978; 46: 402–413
   PubMed Web of Science ®Google Scholar
• Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol 2004; 2171: 255–261
   Google Scholar
• Elger W, Beier S, Pollow K, Garfield R, Shi S Q, Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids 2003; 68: 891–905
   PubMed Web of Science ®Google Scholar
• Oelkers W, Berger V, Bolik A, et al. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin–aldosterone system in normal women. J Clin Endocrinol Metab 1991; 73: 837–842
   PubMed Web of Science ®Google Scholar
• Archer D F, Thorneycroft I H, Foegh M, et al. Long-term safety of drospirenone–estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005; 12: 716–727
   PubMed Web of Science ®Google Scholar
• Weber K T, Brilla C G. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin–angiotensin–aldosterone system. Circulation 1991; 83: 1849–1865
   PubMed Web of Science ®Google Scholar
• Brilla C G, Pick R, Tan L B, Janicki J S, Weber K T. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990; 67: 1335–1364
   Google Scholar
• Rocha R, Chander P N, Khanna K, Zuckerman A, Stier C T, Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31: 451–458
   PubMed Web of Science ®Google Scholar
• Farquharson C A, Struthers A D. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002; 103: 425–431
   PubMed Web of Science ®Google Scholar
• Duprez D A, De Buyzere M L, Rietzschel E R, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998; 19: 1371–1376
   PubMed Web of Science ®Google Scholar
• Barr C S, Lang C C, Hanson J, Arnott M, Kennedy N, Struthers A D. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995; 76: 1259–1265
   PubMed Web of Science ®Google Scholar
• Yee K M, Struthers A D. Aldosterone blunts the baroreflex response in man. Clin Sci (Lond) 1998; 95: 687–692
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme W J, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–717
   PubMed Web of Science ®Google Scholar
• Brown N J. Eplerenone: cardiovascular protection. Circulation 2003; 107: 2512–2518
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–1321
   PubMed Web of Science ®Google Scholar
• La Vecchia C, Decarli A, Franceschi S, Gentile A, Negri E, Parazzini F. Menstrual and reproductive factors and the risk of myocardial infarction in women under fifty-five years of age. Am J Obstet Gynecol 1987; 157: 1108–1112
   PubMed Web of Science ®Google Scholar
• Skafar D F, Xu R, Morales J, Ram J, Sowers J R. Clinical review 91: Female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab 1997; 82: 3913–3918
   PubMed Web of Science ®Google Scholar
• Herrington D M. Hormone replacement therapy and heart disease: replacing dogma with data. Circulation 2003; 107: 2–4
   PubMed Web of Science ®Google Scholar
• Rossouw J E, Anderson G L, Prentice R L, , Writing Group for the Women's Health Initiative Investigators, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Manson J E, Hsia J, Johnson K C, , Women's Health Initiative Investigators, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523–534
   PubMed Web of Science ®Google Scholar
• Anderson G L, Limacher M, Assaf A R, et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–1712
   PubMed Web of Science ®Google Scholar
• Hsia J, Langer R D, Manson J E, et al. Conjugated equine estrogens and coronary heart disease; the Women's Health Initiative. Arch Intern Med 2006; 166: 357–365
   PubMed Web of Science ®Google Scholar
• Adams M R, Kaplan J R, Manuck S B, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in overiectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 1990; 10: 1051–1057
   PubMedGoogle Scholar
• Register T C, Adams M R, Golden D L, Clarkson T B. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol 1998; 18: 1164–1171
   PubMed Web of Science ®Google Scholar
• Liao J K. Endothelium, Nitric Oxide and Atherosclerosis, J A Panza, R OI Cannon. Futura Publishing Co., Inc., Armonk, New York 1999; 119–132
   Google Scholar
• Kleinert H, Wallerath T, Euchenhofer C, Ihrig-Biedert I, Li H, Forstermann U. Estrogens increase transcription of the human endothelial NO synthase gene: analysis of the transcription factors involved. Hypertension 1998; 31: 582–588
   PubMed Web of Science ®Google Scholar
• Simoncini T, Mannella P, Fornari L, et al. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology 2004; 145: 5745–5756
   PubMed Web of Science ®Google Scholar